steviol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: steviol
• 英文别名: (4alpha)-13-Hydroxykaur-16-en-18-oic acid；(1R,5R,9S,13S)-13-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.456
• InChiKey: QFVOYBUQQBFCRH-HFQBERHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  可得然胶 、 steviol 以 乙醇 为溶剂， 反应 72.0h， 以10.6%的产率得到Rubososide
  参考文献：
  名称：

  桉树和小粒咖啡培养细胞对甜菊醇的生物转化

  摘要：

  摘要 从 Eucalyptus perriniana jar 发酵罐中分离出一种新的生物转化产物甜菊醇 19-β-龙胆二糖酯，以及甜菊醇 19-β-吡喃葡萄糖酯和甜菊醇 13-O -β-吡喃葡萄糖苷 19-β-吡喃葡萄糖苷（rubusoside）。给予甜菊醇后培养。仅从小粒咖啡细胞悬浮培养物中分离出甜菊糖苷作为甜菊醇的生物转化产物。

  DOI：

  10.1016/0031-9422(91)83450-y
• 作为产物：
  描述：

  stevioside 在 sodium periodate 、 potassium hydroxide 作用下， 以 水 为溶剂， 反应 17.0h， 以75%的产率得到steviol
  参考文献：
  名称：

  [EN] INHIBITORS OF ANTIBIOTIC RESISTANCE MEDIATED BY ARN T
  [FR] INHIBITEURS DE RÉSISTANCE AUX ANTIBIOTIQUES MÉDIÉE PAR L'ARN T

  摘要：

  本发明涉及通式（I）的二萜化合物，其能够对抗由ArnT酶介导的抗生素耐药性，以及它们作为药物的用途，特别是作为抗生素治疗中的辅助剂，用于治疗抗生素耐药性细菌感染。本发明还涉及将通式（I）的一个或多个化合物与至少另一种活性成分，特别是抗菌剂和/或抗生素，结合在一起的组合物，以及包含一个或多个通式（I）化合物或根据本发明的组合物和至少一种药用可接受的载体和/或载体的组合物，以及包含至少一种化合物、组合物或组合物的产品，特别是医疗器械。此外，本发明涉及使用通式（I）的化合物使细菌对抗菌剂或抗生素敏感化的用途，例如，科利斯汀（多粘菌素E）或多粘菌素B，以及一种体内或体外的方法，用于使细菌对抗菌剂或抗生素敏感化，包括将该细菌暴露于与科利斯汀一起使用的一个或多个通式（I）化合物。

  公开号：

  WO2021014422A1

文献信息

• Method for producing steviol synthetase gene and steviol
  申请人：Yamaguchi Shinjiro

  公开号：US20080271205A1

  公开（公告）日：2008-10-30

  To identify the steviol synthetase gene for research and development of metabolic engineering, for example, for increasing a stevioside producing ability. It was successfully found that CYP714A2 derived from Arabidopsis thaliana is surprisingly steviol synthetase. Furthermore, a system in which a large amount of steviol can be biosynthesized was developed by overexpressing this steviol synthetase gene. The steviol synthetase gene is, for example, a polynucleotide encoding a protein which includes the amino acid sequence of SEQ ID NO: 2.
• INHIBITORS OF ANTIBIOTIC RESISTANCE MEDIATED BY ARNT
  申请人：UNIVERSITÀ DEGLI STUDI DI ROMA "LA SAPIENZA"

  公开号：US20220259249A1

  公开（公告）日：2022-08-18

  The present invention relates to diterpene compounds of general formula (I) capable of contrasting the antibiotic-resistance mediated by the ArnT enzyme, to their use as a medicament, in particular for use as an adjuvant of an antibiotic therapy in the treatment of antibiotic-resistant bacterial infections. The invention relates also to associations of one or more of the compounds of formula (I) with at least another active ingredient, in particular an antibacterial agent and/or an antibiotic, and compositions comprising one or more compounds of formula (I) or the association according to the present invention and at least one pharmaceutically acceptable excipient and/or carrier as well as to products, in particular medical devices, comprising at least a compound, an association or a composition according to the present invention. Moreover, the invention relates to the use of compounds of formula (I) to sensitize a bacterium to an antibacterial agent or an antibiotic, for example, colistin (polymyxin E) or polymyxin B and to an in vivo or in vitro method for sensitizing a bacterium to an antibacterial agent or an antibiotic comprising the exposure of said bacterium to one or more compounds of formula (I) together with colistin.
• [EN] RECOMBINANT MICROORGANISM FOR PRODUCING STEVIOL GLYCOSIDE<br/>[FR] MICRO-ORGANISME RECOMBINANT POUR LA PRODUCTION DE GLYCOSIDE DE STÉVIOL<br/>[KO] 스테비올 배당체 생산용 재조합 미생물
  申请人：AJOU UNIV INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：WO2018012644A1

  公开（公告）日：2018-01-18

  본 발명은 스테비올 배당체 생산용 재조합 미생물 및 스테비올 배당체의 생산 방법에 관한 것이다. 본 발명의 스테비올 배당체 생산용 재조합 미생물은 스테비올모노사이드, 루부소사이드, 스테비올바이오사이드 또는 스테비오사이드를 다량으로 생산하는 우수한 효과가 있다. 따라서, 스테비아의 추출물로부터 직접 스테비올모노사이드, 루부소사이드, 스테비올바이오사이드 또는 스테비오사이드를 분리하는 것이 아닌, 미생물에 도입된 재조합 유전자에 의해 대사경로를 조작함으로써, 간단한 공정만으로도 스테비올모노사이드, 루부소사이드, 스테비올바이오사이드 또는 스테비오사이드를 경제적으로 생산할 수 있어, 상기 스테비올 배당체를 이용하는 천연 감미료 및 음료 등의 식품 산업에 유용하게 이용될 수 있다.
• [EN] INHIBITORS OF ANTIBIOTIC RESISTANCE MEDIATED BY ARN T<br/>[FR] INHIBITEURS DE RÉSISTANCE AUX ANTIBIOTIQUES MÉDIÉE PAR L'ARN T
  申请人：UNIV DEGLI STUDI ROMA LA SAPIENZA

  公开号：WO2021014422A1

  公开（公告）日：2021-01-28

  The present invention relates to diterpene compounds of general formula (I) capable of contrasting the antibiotic-resistance mediated by the ArnT enzyme, to their use as a medicament, in particular for use as an adjuvant of an antibiotic therapy in the treatment of antibiotic-resistant bacterial infections. The invention relates also to associations of one or more of the compounds of formula (I) with at least another active ingredient, in particular an antibacterial agent and/or an antibiotic, and compositions comprising one or more compounds of formula (I) or the association according to the present invention and at least one pharmaceutically acceptable excipient and/or carrier as well as to products, in particular medical devices, comprising at least a compound, an association or a composition according to the present invention. Moreover, the invention relates to the use of compounds of formula (I) to sensitize a bacterium to an antibacterial agent or an antibiotic, for example, colistin (polymyxin E) or polymyxin B and to an in vivo or in vitro method for sensitizing a bacterium to an antibacterial agent or an antibiotic comprising the exposure of said bacterium to one or more compounds of formula (I) together with colistin.

  本发明涉及通式（I）的二萜化合物，其能够对抗由ArnT酶介导的抗生素耐药性，以及它们作为药物的用途，特别是作为抗生素治疗中的辅助剂，用于治疗抗生素耐药性细菌感染。本发明还涉及将通式（I）的一个或多个化合物与至少另一种活性成分，特别是抗菌剂和/或抗生素，结合在一起的组合物，以及包含一个或多个通式（I）化合物或根据本发明的组合物和至少一种药用可接受的载体和/或载体的组合物，以及包含至少一种化合物、组合物或组合物的产品，特别是医疗器械。此外，本发明涉及使用通式（I）的化合物使细菌对抗菌剂或抗生素敏感化的用途，例如，科利斯汀（多粘菌素E）或多粘菌素B，以及一种体内或体外的方法，用于使细菌对抗菌剂或抗生素敏感化，包括将该细菌暴露于与科利斯汀一起使用的一个或多个通式（I）化合物。
• Biotransformation of steviol by cultured cells of eucalyptus perriniana and Coffea arabica
  作者：Yutaka Orihara、Kenji Saiki、Tsutomu Furuya

  DOI：10.1016/0031-9422(91)83450-y

  日期：——

  Abstract A new biotransformation product, steviol 19-β-gentiobiosyl ester, together with steviol 19-β-glucopyranosyl ester and steviol-13- O -β-glucopyranoside 19-β-glucopyranosyl ester (rubusoside), was isolated from Eucalyptus perriniana jar fermentor culture following the administration of steviol. Only rubusoside was isolated as a biotransforination product of steviol from Coffea arabica cell suspension

  摘要 从 Eucalyptus perriniana jar 发酵罐中分离出一种新的生物转化产物甜菊醇 19-β-龙胆二糖酯，以及甜菊醇 19-β-吡喃葡萄糖酯和甜菊醇 13-O -β-吡喃葡萄糖苷 19-β-吡喃葡萄糖苷（rubusoside）。给予甜菊醇后培养。仅从小粒咖啡细胞悬浮培养物中分离出甜菊糖苷作为甜菊醇的生物转化产物。